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Abstract
Background: The use of cellular coreceptors and modulation of cytokine concentrations by HIV to establish a productive
infection is well documented. However, it is unknown whether the expression of these proteins affects the course of HIV
clade A and D disease, reported to have different progression rates.
Methodology/Principal Findings: We investigated whether the number of CD4
+ T-cells expressing CCR5 or CXCR4, the
density of these coreceptors and concentrations of specific immune proteins linked to HIV pathogenesis vary between
individuals infected with HIV clade A or D. We undertook additional analyses stratifying participants by early (CD4.500
cells/ml) or late (CD4,200 cells/ml) disease stage. Whole blood samples were taken from 50 HIV-1 infected individuals drawn
from cohorts in rural south-west Uganda. Late stage participants had less than half the number of CD4
+/CCR5
+ T-cells
(p=0.0113) and 5.6 times fewer CD4
+/CXCR4
+ cells (p,0.0001) than early stage participants. There was also a statistically
significant difference in the density of CXCR4 on CD4
+ cells between clade A and D infected early stage participants (142 [A]
vs 84 [D]; p=0.0146). Across all participants we observed significantly higher concentration of Th1 cytokines compared to
Th2 (66.4 vs 23.8 pg/ml; p,0.0001). Plasma concentrations of IFNc and IL-2 were 1.8 and 2.4 fold lower respectively in Late-
D infected participants compared to Late-A participants. MIP-1b levels also decreased from 118.0 pg/ml to 47.1 pg/ml
(p=0.0396) as HIV disease progressed.
Conclusions/Significance: We observed specific alterations in the abundance of CD4
+/CCR5
+ and CD4
+/CXCR4
+ T-cells, and
concentrations of immune proteins across different HIV clades and as infection progresses. Our results suggest that these
changes are unlikely to explain the observed differences in disease progression between subtype A and D infections.
However, our observations further the understanding of the natural progression of non-clade B HIV infection and how the
virus adapts to exploit the host environment.
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Introduction
Based on the World Health Organisation figures from 2009,
human immunodeficiency virus (HIV) is responsible for 1.9
million deaths and currently infects over 33 million people
worldwide. Isolates of this retrovirus can be split into M, N, O
and a newly identified P group based on phylogenetic analysis [1].
The main group (M) accounts for more than 90% of infections,
while isolates from the N group, limited to roughly 10 isolates, and
the Outlier group (O) have been detected in Cameroon. P group
isolates are closely related to gorilla retroviruses. Within the M
group there are over nine different clades or subtypes, circulating
recombinant forms and unique recombinants, with distinct
geographical distributions. Clade B is predominant in Europe
and North America, with clade C the most common in Africa and
Asia.
There are therapeutic antivirals available that target different
stages of the virus lifecycle. While these are able to control viral
replication the virus is not completely cleared and there is no
efficacious prophylactic vaccine [2]. HIV is therefore a major
burden on many countries but particularly those that are resource-
limited as they also suffer from higher prevalences and incidence
rates. The natural course of the infection can be split into three
stages [3]: (1) Acute phase - lasting several weeks, during which a
spike in viral replication occurs before the immune system is able
to control this. (2) Clinical latency - when the host immune
response is able to limit virus replication. This is usually
maintained for 4–8 years, although it can be greater in long term
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which the CD4
+ T-cells in which the virus replicates are depleted.
The latter is referred to as acquired immunodeficiency syndrome
(AIDS) and multiple co-infections can occur that cause the death
of the infected individual unless effective therapy is employed.
Attachment of the virus is mediated through the binding of the
viral envelope gp120 protein to the cellular CD4 receptor. This
results in a conformational change in the virus protein allowing
another envelope protein (gp41) to interact with the CCR5 or
CXCR4 cellular co-receptor facilitating fusion of the cell
membrane and virus envelope and consequently virus entry.
The importance of chemokine receptors CCR5 and CXCR4 in
HIV-1 infection was first reported in 1995/6 [4,5]. Since then
much work has been undertaken to characterise the interaction
between HIV-1 and the coreceptors it uses in order to further our
understanding of HIV replication and pathogenesis (reviewed
elsewhere [6]). As mentioned, the early stages of HIV infection are
mainly characterised by a high CD4 count (.500 cells/ml) and the
majority of circulating viruses are CCR5-tropic (R5). These
exhibit slow/low replication kinetics, are non-syncytium inducing
and predominantly infect activated CD4
+ cells and macrophages
[7,8]. In contrast, at the late stage of disease progression (CD4
count less than 200 cells/ml) CXCR4 using virus isolates (X4) are
abundant, mainly in clade B infected patients, and exhibit rapid
replication kinetics. They are characterised by the ability to form
syncytia and infect memory and naı ¨ve CD4
+ cells [9]. The fact
that these slow and rapid phenotypes are predominantly observed
at early and late stages of HIV disease respectively can partly be
explained by the fact that R5 HIV-1 accounts for the vast majority
of infections [6], although possible cases of X4 HIV-1 transmission
have been reported [10].
Various immunological and viral factors may affect coreceptor
expression and consequently influence how quickly HIV positive
individuals progress to AIDS. For example, specific HLA alleles
have been shown to influence the potency of anti-Gag T-cell
responses [11] and the actual switch in coreceptor usage, or
phenotypic switch, from R5 to X4, is associated with faster CD4
decline and consequently a more rapid HIV disease progression
[12,13,14]. However, as X4 isolates are more sensitive to
neutralising antibodies, it could be that they are ‘‘opportunistic
infections’’ appearing at late stages of HIV disease when the
humoral host immune response has been greatly exhausted. It
should also be noted that while this switch has primarily been
reported in clade B [13] it has also occurred in clades C [15,16], A
and D [17,18] to varying degrees and some viral isolates are able
to use both CCR5 and CXCR4 [19] or alternative coreceptors
[20,21] in vitro (also reviewed elsewhere [7]).
In HIV-1 positive cohorts of African adults, individuals infected
with clade D progressed faster to AIDS than those with clade A
[22,23,24]. This difference in disease progression could be due to
clade D viruses switching from R5 to X4 phenotype earlier in
infection, at higher CD4
+ cell counts, than clade A isolates [25].
However, cellular factors such as interleukin-7 (IL-7), IL-4, tumour
necrosis factor a (TNFa), RANTES and interferon c (IFNc), as
well as the HIV-1 accessory protein Nef, have all been shown to
alter the level of chemokine receptor surface expression.
Therefore, they may also influence the rate of disease progression
[26,27,28,29]. Similarly, it is possible that a select group of
immune proteins, so called anti-HIV cytokines and chemokines
known to influence the risk of HIV-1 infection and consequent
disease progression [30], could play a role in the more rapid
disease progression observed in clade D infection.
Here we report the findings of a cross-sectional study to
investigate whether there are differences in the quantity of CD4
+
T-cells expressing CCR5 or CXCR4, the cell surface density of
these receptors and the concentrations of certain anti-HIV-1
cytokines and chemokines between clade A or D infected
participants. We also investigate the levels of these factors in
individuals at early (CD4.500 cells/ml) or late (CD4,200 cells/
ml) stages of HIV-1 disease.
Methods
Objectives
To determine if the abundance of HIV-1 coreceptors and anti-
HIV cytokines/chemokines differs between clade A and D HIV-1
infected individuals. To compare the same variables at early and
late stages of HIV-1 disease.
Participants
Whole blood samples were taken from 50 highly active
antiretroviral therapy (HAART) naı ¨ve individuals. Twenty-five
individuals had a CD4 count of less than 200 cells/ml and 25 a
CD4 count of more than 500 cells/ml. The participants were
drawn from two clinical research cohorts, both of which were
established by the MRC/UVRI Uganda Research Unit on AIDS
in a rural area of south-west Uganda. Thirty seven individuals
(none of whom were receiving HAART at the time of this study)
were selected from the Rural Clinical Cohort (RCC) in Masaka
district [31]. Of these individuals 25 had a CD4 count .500 cells/
ml and 12 had a CD4 count of ,200 cells/ml. As individuals in the
RCC are offered HAART, there were few with a CD4
+ T-cell
count below 200 cells/ml who were still HAART naı ¨ve so we were
not able to recruit all participants from the RCC. Therefore, the
remaining 13 individuals with low CD4 counts were selected from
a cohort recruited to investigate an innovative intervention against
cryptococcal disease also based in Masaka district [32]. None of
the participants had current opportunistic infections. To enable a
comparison of immune markers between HIV negative and
positive individuals, four HIV negative participants were random-
ly selected from the RCC.
HIV coreceptor staining
Blood was collected in EDTA vacutainers (Becton Dickinson
[BD], UK) and transported to the laboratory where it was either
used immediately or plasma isolated and stored. For each sample,
100 ml aliquots of fresh, whole blood were stained with CD3-
FITC, CD4-PerCP-Cy5.5, and either CCR5-PE, CXCR4-PE or
their respective isotype controls (BD PharMingen [BDP], UK) to
determine the percent of CD4
+ cells expressing CCR5 or CXCR4.
A FACScan and CellQuest Pro (BD, UK) were used to acquire
3x10
5 events for each condition. Each sample was gated on the
CD3
+/CD4
+ population before any analysis was undertaken. The
relative size (forward scatter
2) of the CD4
+ T-cells for each
individual was recorded along with the mean fluorescent intensity
(MFI) of CCR5 and CXCR4. We used these values to calculate
the density of CCR5 and CXCR4 on the selected cell population,
one possible method for determining relative receptor densities.
Cytometric bead array (CBA)
A human cytokine/chemokine CBA flex set kit (IFNc, TNFa,
IL-2, IL-10, IL-5, IL-4, MIP-1a, MIP-1b and RANTES) was used
as described by the manufacturer (BD, UK) with 50 mlo f
cryopreserved plasma from each participant. CBA Analysis
Software (BD, UK) was used to analyse the data generated. The
standards for this assay cover 10–5,000pg/ml, however the
standard curve defines the outer limits of detection. The
theoretical limit of detection is defined as the corresponding
HIV Effect on Immune Markers
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fluorescence of the negative control (0 pg/ml) using a 4- or 5-
parameter curve. Therefore, it is possible to determine values for
samples that fall within the linear range of the curve, 0–
15,000 pg/ml for the dilution series we used in this study.
HIV testing, subtyping and viral load
HIV serostatus was confirmed using two commercial ELISA kits
(Wellcozyme Recombinant HIV EIA (Murex Biotech, UK) and
Recombigen HIV-1/HIV-2 [Trinity Biotech, UK]) and a western
blot kit (New Lav Blot 1 [Bio-Rad, France]). CD4
+ T-cell counts
were determined using the BD FACScount system (BD, UK). HIV
viral load testing and genetic subtyping was undertaken using
qRT-PCR and direct sequencing of the reverse transcriptase gene
[33]. For 5 participants on whose specimens sequencing was not
successful, heteroduplex mobility assays (HMA) were undertaken
[34].
Statistical methods
To determine whether variables were normally distributed
D’Agostino & Pearson omnibus normality tests were performed. If
all or the majority of data in each set was normally distributed
mean values were used, otherwise median values were cited.
Analyses undertaken were pairwise comparisons rather than
factorial analyses involving the four groups. Therefore, corre-
sponding two-sample t-tests (for variables which could be regarded
as being normally distributed) or Mann-Whitney tests (for
variables for which we could not assume normality) were
performed to examine whether the selected variables differed
between the two groups. All reported p-values are two-sided using
a level of significance of 0.05. Statistical analyses were conducted
using GraphPad Prism (GraphPad Software, San Diego, USA).
Ethical considerations
Written informed consent was obtained from all participants
and ethical approval for the study was given by the ethics
committee of the Uganda Virus Research Institute and the
Uganda National Council for Science and Technology. HAART
was provided to all eligible participants shortly after specimen
collection for this study.
Results
For analyses participants were placed into one of fours groups
according to disease stage and HIV subtype: Early-A, Early-D,
Late-A and Late-D. Of the 50 participants enrolled in this study
clades A and D were the only subtypes present (25 participants
each; Figure 1). Sixty percent of early stage participants were
infected with clade A while this was reversed in the late stage
group with 60% infected with clade D (Table 1). The mean CD4
+
count for early stage individuals was 736 cells/ml (95% confidence
interval [C.I.] 663–808) compared to 146 cells/ml (95% C.I. 122–
169) for the late stage group. The CD4
+ counts were similar for A
and D infected participants at both time points (Table 1). As
expected the mean CD4
+ count in HIV negative participants was
much higher (950 cells/ml [95% C.I. 513–1388]; n=4). There
was a similar age distribution between the four groups, with the
Early-D group having the highest (40.3 [32.1–48.4]; mean age
[95% C.I.] in years). There were more females than males in the
late group (64% vs 36%) but this was skewed by the Late-A group
comprising 90% females, a chance result due to the sampling
strategy used. As expected, individuals in the late group were also
at more advanced stages of HIV disease according to WHO
staging compared to early individuals (Early = 2.2 [1.8–2.6],
Late = 2.8 [2.5–3.1]; mean stage [95% C.I.] in years). The
infecting subtype did not affect WHO disease staging. There was
a statically significant difference in HIV viral load measurements
between participants in early versus late time points (early: 14,021
[4058–23983]; mean viral load [95% C.I.]. Late: (132,203
[44,944–219462]; mean viral load [95% C.I.]. p=0.0126;
unpaired t-test). While there was a trend for the Early-D and
Late-D groups to have higher viral load measurements than the
corresponding clade A infected groups, this difference was not
significant (Table 1).
We determined whether the abundance of HIV coreceptors,
quantified by either the absolute number of total CD4
+ T-cells
expressing CCR5 or CXCR4, or their density on those cells,
varied between clades or during the course of HIV infection. Prior
to analysis each sample was gated on the CD3
+/CD4
+ cell
population and statistical testing showed the majority of the
coreceptor data obtained for this analysis was normally distributed
(D’Agostino & Pearson omnibus normality test; data not shown).
As a benchmark against which to compare results from HIV
positive individuals, we determined the abundance of CCR5 and
CXCR4 T-cells in four uninfected RCC participants. Absolute
numbers of CD4
+/CCR5
+ and CD4
+/CXCR4
+ cells in HIV
negative individuals were 99 cells/ml (55-143 95% C.I.) and 922
cells/ml (490-1354 95% C.I.) respectively. Analysing all HIV
infected participants, there was 4.8 fold more CD4
+ T-cells
expressing CXCR4 (421 cells/ml [329-513]; mean [95% C.I.])
than CCR5 (19 cells/ml [13–25]; mean [95% C.I.]; p,0.0001,
Figure 1. Radial tree showing degree of identity between the
study participants’ HIV isolates. RT-PCR was undertaken to amplify
sequence from the reverse transcripase gene that was subsequently
used to construct the tree. The branch lengths and scale correspond to
the number of substitutions/mutations per site.
doi:10.1371/journal.pone.0019902.g001
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+/CCR5
+ cells in
participants at a late time point in HIV-1 infection was 2.2 fold
lower compared to those at early stage groups, 12 and 26
respectively (p=0.0113, unpaired t-test; Figure. 2A). The same
trend was seen when comparing the mean number of CD4
+ cells
expressing the CXCR4 receptor in late vs. early stage groups. This
was significantly higher in early stage HIV-1 infected participants
than those at late time points (714 to 128 cells/ml; p,0.0001,
unpaired t-test; Figure. 2A).
Similar to the difference observed in the absolute number of T-
cells expressing the two coreceptors, the density of the CXCR4
(104.0 [85.06-122.9]; mean density [95% C.I.]) across all
participants was 5.3 times higher than CCR5 (19.47 [17.15–
21.79]; mean density [95% C.I.]; p,0.0001, unpaired t-test).
These densities were also lower than mean densities observed in
HIV negative participants (CCR5 = 27.2 and CXCR4 = 120).
The density of the CCR5 coreceptor on the surface of CD4
+ cells
in HIV positive participants was similar between the four groups.
However, the mean density of CXCR4 was 1.7 fold lower in the
Early-D group (83.94 [55.84–112]; mean density [95% C.I.]) than
the Early-A group (142.2 [108.6–176.3]; mean density [95% C.I.];
p=0.0146; unpaired t-test; Figure 2B).
Table 1. Characteristics of study participants.
HIV disease stage Total (n=50)a
Early (CD4.500) Late (CD4,200)
Clade A
a Clade D Clade A Clade D
Number of participants 15 10 10 15 50
Drawn from the RCC
b 15 10 5 7 37
Drawn from the CTR
b 00 5 8 1 3
Age (years; mean) 36.7 40.3 36.8 37.1 37.6
[30.3-43.2] [32.1-48.4] [26.3-47.3] [33.8-40.4] [34.5-40.6]
Gender: F/M (%) 47/53 50/50 90/10 56/44 56/44
WHO HIV disease 1: 33; 2:2 7 1:2 0 ;2:3 0 1:0 ;2:2 0 1:1 3 ;2:2 0 1:1 8 ;2:2 4
stage (%) 3: 33; 4:7 3:4 0 ;4:1 0 3:6 0 ;4:2 0 3:5 4 ;4:1 3 3:4 6 ;4:1 2
Mean CD4
+ T-cell 724 754 147 145 441
count (cell/ml) [624-823] [628-879] [116-179] [108-182] [348-533]
Mean viral load
a 8,142 20,487 85,126 108,687 59,273
(copies/ml) [3,115-13,169] [1,134-42,108] [14,268-184,519] [22,167-195,207] [25,408-93,139]
aThe data shown in this table were calculated using all HIV positive participants enrolled in this study (n=50), apart from HIV envelope subtype data and viral load
measurements, where samples to obtain these data were not available for five participants. For these samples, four from the early group and one the late group,
existing HMA data was used to subtype.
bRCC = Rural Clinical Cohort; CTR = Cryptococcal Trial Recruitment. The 95% confidence intervals for age, CD4
+ T-cell count and viral load are given in square brackets
beneath the mean value for these variables.
doi:10.1371/journal.pone.0019902.t001
Figure 2. Coreceptor abundance stratified by HIV disease stage and clade. The mean absolute number of CD4
+/CCR5
+ and CD4
+/CXCR4
+ T-
cells (A) and mean density of CCR5 and CXCR4 on CD4
+ cells (B) are shown, with error bars representing standard error of the means. Results are
shown for samples from participants at early (black and heavy shading bars) or late (light shading and white bars) stages of infection and for
participants infected with HIV-1 clade A (black and light shading bars) or D (heaving shading or white bars). * = p,0.05 and ** = p,0.0001,
calculated using unpaired t-test.
doi:10.1371/journal.pone.0019902.g002
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influence the clinical course of HIV-1 disease progression and the
expression of HIV CCR5 and CXCR4 coreceptors, we measured
the level of certain anti-HIV-1 cytokines (IFNc, TNFa, IL-2, IL-
10, IL-5 and IL-4) and chemokines (MIP-1a, MIP-1b, RANTES)
in the plasma of each study participant. Most of the cytokine data
was not normally distributed (D’Agostino & Pearson omnibus
normality test; data not shown) so median values and correspond-
ing significance tests were used for the analysis. These revealed
that the combined concentrations of Th1 cytokines in all
participants was significantly higher than Th2 concentrations
(66.4 vs 23.9 pg/ml; p,0.0001, Mann Whitney test; Figure 3).
The observed increase in Th1 cytokines (62.7 vs 71.0 pg/ml) and
slight decrease in Th2 cytokines (24.6 vs 23.1 pg/ml) in individuals
at the late stage of HIV disease when comparing with those at the
early stage, were not significant (p=0.4728 and p=0.7269
respectively, Mann Whitney test; Figure 3A). There was a small
decrease in the concentration of Th1 cytokines (58.6 [D] vs 63.9
[A] pg/ml) and similar levels of Th2 cytokines (25.5 [D] vs 25.9
[A] pg/ml) in clade D infected participants compared to clade A
infected (Figure 3B). However, neither variation was significant.
Median concentrations of individual cytokines and chemokines
were analysed across the four groups: Early-A, Early-D, Late-A
and Late-D. These revealed comparable levels in the majority of
participants. The range of median concentrations was 0–11.1 pg/
ml (Figure 4) apart from IFNc (50.70 pg/ml; Figure 4A), MIP-1b
(53.39 pg/ml; Figure 4E) and RANTES (10611 pg/ml; Figure 4F).
However, IFNc levels in participants in the Late-D group were
lower than those in Late-A (45.8 vs 68.7 pg/ml; p=0.0065;
Figure 4A). A similar pattern was observed when we measured IL-
2 (0.0 vs 9.9 pg/ml; p=0.0087; Figure 4C). Finally, there was a
significant decrease in MIP-1b as the course of HIV disease
progressed (81.9 vs 26.7 pg/ml; p=0.0022; Figure 4E).
Discussion
We have previously shown that HIV-1 clades A and D are
predominant in our study population (42% and 58% respectively
[35]). We observed a similar distribution within our current study
participants, 50% for clade A and D. Analysis undertaken based
on infecting HIV clade revealed that, with the exception of a lower
density of CXCR4 on CD4
+ T-cells for Early-D participants and
lower concentrations of IFNc and IL-2 for Late-D participants,
levels of CCR5, CXCR4, cytokines and chemokines were
comparable. These findings suggests that the level of coreceptor
and cytokine/chemokine expression may not be the cause of the
accelerated disease progression we previously reported in subtype
D infection participants within our cohorts [23]. However, this
could be caused by the phenotype switch occurring at an earlier
disease stage [25] or a result of subtype D individuals having a
higher viral load than subtype A individuals [36] (table 1).
However, there could be other virological, cellular or immuno-
logical pressures influencing the above observations.
We observed a similar trend of marginally higher mean CD4
+
counts in Ugandan women (483 [342–623 95% C.I.]) compared to
Ugandan men (473 [345–601 95% C.I.]; p=0.9197) in a previous
study [37]. As neither of these trends was statistically significant it
is unlikely that the high proportion of females in the Late-A group
would lead to a bias in the other results reported in our present
study. However, as expected the overall number of T-cells
expressing the HIV coreceptors was higher in HIV negative
participants than among HIV positive participants. Our data
reveal that as infection progressed a concurrent depletion of the
absolute number of CD4
+/CCR5
+ cells and CD4
+/CXCR4
+ cells
occurred when comparing Early and Late stage groups. This
seems counterintuitive to what we would expect if coreceptors
were playing an active role in determining HIV phenotype. If the
abundance of coreceptor expressing cells was driving the
phenotypic switch we might observe higher levels of CD4
+/
CCR5
+ cells in samples from individuals infected at early stages
compared to those at late stages. Therefore, these variations are
more likely to be a consequence of disease progression and not the
cause of the coreceptor switch. This conclusion is consistent with a
recent study by Poveda et al. who reported findings on the role of
viral phenotype in pathogenesis of HIV-1 clade B [38]. That study
also suggested that the phenotypic switch is a consequence rather
than the cause of a decline in CD4 count.
The observed differences in numbers of CD4
+/CCR5
+ and
CD4
+/CXCR4
+ cells between early and late disease stage groups
in our study are consistent with those reported in other cohorts
[39,40]. However, those studies have not reported the density of
CCR5 or CXCR4, or immune protein concentrations in HIV
clade A and D infected individuals at early or late stages of HIV
infection, all of which have been shown to influence HIV disease
progression [30]. It is likely that the changes in the number of
CCR5 and CXCR4 expressing CD4
+ T-cells in our study were
due to virus-mediated T-cell killing. This conclusion is also in
agreement with the viral load data of the study participants.
Figure 3. Total cytokine concentrations in study participants. Bar graphs represent cytokines concentrations (pg/ml) as a proportion of the
total concentration of Th1 and Th2 cytokines measured. These have been stratified by HIV-1 disease stage (A) or HIV-1 clade (B) with shaded and
patterned areas corresponding to Th1 and Th2 cytokines respectively. ** = p,0.0001 (Mann Whitney test) for total Th1 vs Th2 cytokines when
compared across all HIV positive study participants (n=50).
doi:10.1371/journal.pone.0019902.g003
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+ and
CXCR4
+ T-cells which inversely correlated with the observed
higher viral loads in these groups (CCR5 - r=20.4 p=0.0119;
CXCR4 - r=20.4 p=0.0029; Spearman’s Rank Correlation).
However, HIV is known to cause immune activation, which can
modulate the expression of CCR5 and CXCR4 [40,41]. The high
levels of CD4
+/CXCR4
+ cells and density of CXCR4 we found
compared to CCR5 may also explain the greater pathogenicity of
X4 HIV-1 observed in individuals infected with CXCR4 using
HIV [42].
Various cytokines and chemokines have previously been
implicated in influencing expression of CCR5 and CXCR4 on
the surface of CD4
+ cells [26,27]. Because of this observation and
taking the type 1/type 2 cytokine model of immune response to
HIV-1 into account which predicts a switch in the balance of
cytokines from Th1 to Th2 resulting in a more rapid disease
progression, we were interested to know if the concentration of
such immune proteins differed between the four groups of
participants. Not only would this provide a better understanding
of HIV disease progression, but it may also help to elucidate what
triggers the phenotypic switch. Our data showed that the
concentrations of a select group of cytokines/chemokines, when
compared individually, differed only marginally between each
group. However, larger and significant differences were apparent
in the overall concentrations of Th1 and Th2 cytokines when all 50
participants were analysed. Th1 cytokines made up over 60% of
the total concentration of cytokines measured. IFNc accounted for
the majority of the Th1 response and was primarily responsible for
the increase in Th1 response as disease progressed. This is to be
expected though as IFNc is one of the main antiviral cytokines and
viral load values were much higher in Late group participants.
When analysing participants according to disease stage, the non-
significant trend showing a decrease in Th2 and increase in Th1
cytokines is contrary to what we would predict but could be due to
the fact that only a select group of immune proteins was measured.
It is possible that other Th2 responses could be more substantially
activated as the course of HIV infection progresses or that HIV
primarily targets Th1 expressing cells at early times of infection so
that this cell population becomes more rapidly depleted. In
agreement with this possibility, analysis of cytokine/chemokine
concentrations in our study failed to reveal a correlation with levels
of CD4
+/CCR5
+ or CD4
+/CXCR4
+ cells, suggesting they are not
directly driving the alternations in T-cell subsets (data not shown).
It is of interest to note that while we observed high median
concentrations of IFNc, MIP-1b and RANTES, there were low
levels of IL-2, a cytokine that plays a key role in stimulating CD8
+
T-cell responses. These differences could be caused by a number
of environmental factors, such as opportunistic infections, time of
sampling and age. However, we were able to minimise the possible
influence of such factors through the study design, e.g. all
Figure 4. Individual profiles for all cytokines and chemokines measured. Vertical scatter plots show the median plasma concentration
(horizontal black line; pg/ml) for the anti-HIV-1 cytokines (IFNc, TNFa, IL-2, IL-10, IL-5 and IL-4) and chemokines (MIP-1a, MIP-1b and RANTES)
measured as part of this study. Participants were analysed in four groups based on disease stage and HIV clade: Early-A, Early-D, Late-A and Late-D.
*=p ,0.05 and ** = p,0.0001, calculated using Mann Whitney test.
doi:10.1371/journal.pone.0019902.g004
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tions, blood samples were drawn at clinics held at the same time
each day and the mean age and age range were similar across all
groups. It is highly likely that the larger concentrations of IFNc,
MIP-1b and RANTES were due to their central role in controlling
viral infections as they have previously been shown to potently
inhibit HIV infection [43]. The level of these three predominant
proteins did not correlate with CD4
+ count or viral load (data not
shown). Together these results suggest that the alterations we
observed in certain cytokines and chemokine concentrations were
either the result of a clade specific immune response or simply too
small to be considered clinically relevant. However, it is
noteworthy that the cytokine concentrations were within the same
range as previously reported in another HIV positive Ugandan
cohort [44]. Compared to the HIV negative Ugandans enrolled in
that study, cytokine concentrations in our HIV positive partici-
pants were elevated, which could be explained by the highly
activated status of their immune system due to HIV infection.
The changes observed in the abundance of CCR5 and CXCR4
chemokine receptors on CD4
+ T-cells and of cytokines/chemo-
kines during the natural course of non-clade B HIV-1 infection
suggests that the phenotypic switch is not driven by changes in the
levels of these receptors or anti-HIV cytokines. In addition, these
observations are unlikely to explain the observed differences in
disease progression between subtype A and D infected individuals.
The factors responsible for triggering the switch in HIV coreceptor
usage have yet to be conclusively identified. Our results further
illustrate the complexity of the interaction between the virus and
the host in HIV pathogenesis. Further work into the mechanism
by which HIV manipulates the host environment as disease
progresses may help tailor therapeutic interventions to each
individual and also facilitate the development of new strategies to
slow or halt the course of infection.
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